David Maloney, M.D., Ph.D.
Dr. David Maloney received his MD and PhD in cancer biology from Stanford University, his internship and residency in internal medicine at Brigham and Woman’s Hospital, and a fellowship in oncology at Stanford.
While at Stanford, Dr. Maloney worked with Dr. Ronald Levy to develop monoclonal antibody treatments for lymphoma and has since participated in several clinical trials studying these agents. His current research focuses on the mechanisms of action of monoclonal antibodies and the use of non-myeloablative allogeneic transplantation for the treatment of hematologic malignancies.
Dr. Maloney is currently a member of the American Society of Hematology, American Society of Clinical Oncology, the Southwest Oncology Group Lymphoma Committee and the National Comprehensive Cancer Network (NCCN) Committee on Hodgkin’s Disease.
Throughout his career, Dr. Maloney has authored and co-authored many articles that have appeared in publications such as the Journal of Immunology, the New England Journal of Medicine, and Blood, focusing on antibody therapy, lymphoma, myeloma and transplantation.
WM Clinical Trials: https://clinicaltrials.gov/ct2/results?term=Maloney+Waldenstrom%27s